RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer

Berta Luzón-Toro1,2, Leticia Villalba-Benito1,2, Raquel María Fernández1,2

  • 1Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.

Insights

This study validates novel long non-coding RNAs (lncRNAs) in medullary thyroid cancer (MTC). Preliminary results suggest RMST, FTX, IPW, and RMRP play a role in MTC pathogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor with sporadic (sMTC) and inherited (MEN2) forms.
  • Multiple Endocrine Neoplasia type 2 (MEN2) is linked to RET proto-oncogene mutations.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their role in cancer, but their involvement in MEN2 is unexplored.

Discussion:

  • This study validates previously identified lncRNAs (RMST, FTX, IPW, RMRP) in a larger cohort of MTC patients.
  • RT-qPCR analysis was performed on formalin-fixed paraffin-embedded tissues from MEN2 and sMTC patients.
  • The expression levels of RMST, FTX, and IPW were found to be up-regulated, while RMRP was down-regulated.

Key Insights:

  • RMST, FTX, and IPW show potential as up-regulated biomarkers in MTC pathogenesis.
  • RMRP demonstrates potential as a down-regulated biomarker in MTC pathogenesis.
  • These findings support the involvement of specific lncRNAs in the development of MTC.

Outlook:

  • Further research is needed to elucidate the precise mechanisms by which these lncRNAs influence MTC.
  • Validation in larger, diverse patient cohorts and functional studies are crucial.
  • These lncRNAs may represent novel therapeutic targets or diagnostic markers for MTC.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K